2020 Prescription Drug Policy Toolkit for State Lawmakers | Association for Accessible Medicines
Welcome Message - Blog from AAM President and CEO Dan Leonard: Generics: The Bridge to A Vaccine.
You can protect patient access and savings in your state.

2020 Prescription Drug Policy Toolkit for State Lawmakers

Learn More About the Four Types of State Drug Policy Bills

Your Questions Answered

What effect do generic drugs have on health care spending?

Generic and biosimilar prescription drugs drive savings for patients and taxpayers. In 2018 alone, generic prescription medicines saved the U.S. health care system $293 billion — and a whopping $2 trillion in the past 10 years. According to a December 2019 Health Affairs study, “Greater use of generic drugs in 2018 put downward pressure on prices.”

Read more in The Case for Competition: The 2019 Generic Drug & Biosimilars Access & Savings in the U.S. Report

2019 Generic Drug & Biosimilar Savings in the U.S. Report

Read the Fact Sheet | Download the Full Report

So what’s behind rising drug prices?

Brand-name drug prices continue to rise faster than inflation. In 2016, brand drugs accounted for only 10 percent of prescriptions dispended, but more than 74 percent of total spending. Conversely, generics made up 90 percent of prescriptions, but only 23 percent of spending.

How does the generic prescription drug market differ from the brand-name market?

Generic manufacturers deliver large volumes of low-margin products and regularly adjust prices up and down to react to market conditions. Generics are extremely susceptible to minor market changes, including new regulatory reporting requirements. The hypercompetitive and rapidly changing nature of generic drug markets leaves generic drugs particularly vulnerable to drug shortages. The highly competitive generic market has more than 200 manufacturers and only three primary purchasers who leverage their power to keep prices very low. The nature of competitive generic markets can prevent generic manufacturers from raising prices to reflect changing demand or increases in manufacturing costs for products. This results in a dynamic landscape in which manufacturers regularly enter and exit markets as conditions change.

What role do pharmacy benefit managers (PBMs) play?

Unlike brand manufacturers, which sell to pharmacy benefit managers (PBMs) and negotiate formulary placement based on rebates, generic manufacturers sell to wholesalers. Three large wholesale/pharmacy buying consortia control more than 90% of the market for generic drug purchasing. They then sell those drugs to pharmacies – with pricing and distribution outside the control of manufacturers. Wholesalers also generate revenue from sales to pharmacies and fees related to other services provided to customers. Like any other supply chain market, wholesalers can capitalize on price fluctuations – especially those in the generic market. The price a patient pays for a generic drug is affected not only by pricing markups by the wholesaler and pharmacy, but also by insurance copay and formulary design choices made by insurance plans and PBMs.

What is the economic impact of the generic pharmaceutical industry?

AAM members provide more than 36,000 jobs at nearly 150 facilities and manufacture more than 61 billion doses of prescription medicines in the United States every year.

More Resources

Interactive U.S. Savings Map: See how savings in your state compare to the rest of the country 

2019 U.S. Savings Map


Generic Medicines: Answers to Your Questions about Safety and Effectiveness

Generic Medicines: Answers to Your Questions about Safety and Effectiveness


Generics and Biosimilars Industry PowerPoint for State Legislators 

AAM State Lawmakers PPT



Please see below for shareable resources, press releases and other content relating to this issue. You can also use the search bar in the header of our website to search for specific keywords across all content on the site.

PDFApr 03, 2019Ericka Nguyen
Drug Price Transparency State Brief
Download |
PDFSep 05, 2019Ericka Nguyen
Patent Settlements that Resulted in Early Entry of Generics
Download |
PDFApr 03, 2019Ericka Nguyen
Rate-Setting State Brief
Download |
Press Release Oct 8, 2019 Rachel Schwartz
AAM Response to CA Governor Newsom Signing AB 824
Press Release Feb 19, 2019 Rachel Schwartz
Patient Victory: Supreme Court Denies Review of Drug Pricing Law HB 631

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.